Single neonatal dose of gene therapy extends survival in mouse model of POLG mitochondrial disease
A preprint describes gene replacement therapy that preserved motor coordination and improved survival in mice lacking functional POLG, the most commonly mutated single nuclear gene in mitochondrial disease.
A preprint posted to bioRxiv on 18 November 2026 reports that a single dose of gene replacement therapy administered to newborn mice lacking functional POLG — the gene encoding the mitochondrial DNA polymerase gamma — preserved motor coordination and significantly extended survival compared with untreated animals.
POLG mutations are the most common single nuclear gene cause of mitochondrial disease in humans, encompassing a clinical spectrum that ranges from severe early-onset conditions such as Alpers syndrome and myocerebrohepatopathy to milder adult-onset presentations including progressive external ophthalmoplegia. No disease-modifying treatments currently exist; available supportive therapies do not halt progression.
The preprint authors describe a gene replacement approach delivered in the neonatal window, taking advantage of the rapid tissue growth in early life to achieve broad biodistribution. The specific vector, dose, and institutional affiliation were not fully detailed in the available lede text. As a preprint, this work has not yet undergone peer review, and results in mouse models do not straightforwardly predict outcomes in patients with POLG disease, whose genetic backgrounds and disease trajectories are highly variable.
The study is of particular relevance to researchers working in mitochondrial disease, to genetic counsellors who work with families affected by POLG conditions, and to educators covering gene therapy strategies for recessive nuclear-encoded mitochondrial disorders.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
POLG is a gene that helps copy the DNA found inside the energy-producing parts of cells called mitochondria. Faults in POLG cause a range of serious mitochondrial diseases, some of which begin in early childhood and have no effective treatments. Scientists have published a preprint — an early research report that has not yet been checked by independent experts — describing an experiment in mice where a single dose of gene replacement therapy given shortly after birth helped the mice live longer and kept their movement better than untreated mice with the same gene fault. This is mouse research at an early stage, and it is not known yet whether a similar approach could work safely in people. Researchers will need to do much more work before any treatment could be tested in patients. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary sourcePreprint bioRxiv · 2026-11-18Single-dose neonatal gene therapy preserves motor coordination and extends survival of Polg-deficient mice